Publications by authors named "Andrew Reikes"
Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022.
J Am Pharm Assoc (2003)
February 2024
Article Synopsis
- A recent study analyzed the usage trends of GLP-1 receptor agonists, which are linked to significant weight loss, in a large healthcare database from the University of California Health between 2014 and 2022.
- The results showed a substantial increase in users, particularly for Ozempic, which jumped from 569 in 2019 to 22,891 in 2022, indicating a growing demand for these medications among individuals with type 2 diabetes, cardiovascular disease, and those who are overweight or obese.
- The findings suggest a shift in how these medications are utilized, highlighting the need for informed decision-making and further research to understand their long-term impact.
Background: The prevalence of medical misinformation on the Internet has received much attention among researchers concerned that exposure to such information may inhibit patient adherence to prescriptions. Yet, little is known about information people see when they search for medical information and the extent to which exposure is directly related to their decisions to follow physician recommendations. These issues were examined using statin prescriptions as a case study.
View Article and Find Full Text PDFAims: To examine the relative contribution of glycaemic control (HbA1C) and depressive symptoms on diabetes-related symptom burden (hypoglycaemia and hyperglycaemia) in order to guide medication modification.
Methods: Secondary analysis of medical records data and questionnaires collected from a racially/ethnically diverse sample of adult patients with type 2 diabetes (n = 710) from seven outpatient clinics affiliated with an academic medical centre over a 1-year period as part of the Reducing Racial Disparities in Diabetes: Coached Care (R2D2C2) study.
Results: Results from linear regression analysis revealed that patients with high levels of depressive symptoms had more diabetes-related symptom burden (both hypoglycaemia and hyperglycaemia) than patients with low levels of depressive symptoms (βs = 0.